{"doc_id": "33189161", "type of study": "Therapy", "title": "", "abstract": "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited.\nWe assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19.\nWe did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites.\nAdults aged 18 years or older and admitted to hospital with COVID-19 symptoms, with a positive RT-PCR or point-of-care test, or both, were randomly assigned (1:1) to receive SNG001 (6 MIU) or placebo by inhalation via a mouthpiece daily for 14 days.\nThe primary outcome was the change in clinical condition on the WHO Ordinal Scale for Clinical Improvement (OSCI) during the dosing period in the intention-to-treat population (all randomised patients who received at least one dose of the study drug).\nThe OSCI is a 9-point scale, where 0 corresponds to no infection and 8 corresponds to death.\nMultiple analyses were done to identify the most suitable statistical method for future clinical trials.\nSafety was assessed by monitoring adverse events for 28 days.\nThis trial is registered with Clinicaltrialsregister.eu (2020-001023-14) and ClinicalTrials.gov (NCT04385095); the pilot trial of inpatients with COVID-19 is now completed.\nBetween March 30 and May 30, 2020, 101 patients were randomly assigned to SNG001 (n=50) or placebo (n=51).\n48 received SNG001 and 50 received placebo and were included in the intention-to-treat population.\n66 (67%) patients required oxygen supplementation at baseline: 29 in the placebo group and 37 in the SNG001 group.\nPatients receiving SNG001 had greater odds of improvement on the OSCI scale (odds ratio 2\u00b732 [95% CI 1\u00b707-5\u00b704]; p=0\u00b7033) on day 15 or 16 and were more likely than those receiving placebo to recover to an OSCI score of 1 (no limitation of activities) during treatment (hazard ratio 2\u00b719 [95% CI 1\u00b703-4\u00b769]; p=0\u00b7043).\nSNG001 was well tolerated.\nThe most frequently reported treatment-emergent adverse event was headache (seven [15%] patients in the SNG001 group and five [10%] in the placebo group).\nThere were three deaths in the placebo group and none in the SNG001 group.\nPatients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials.\nSynairgen Research.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 108}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 137}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 54}, {"term": "COVID-19 symptoms", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 77}, {"term": "positive RT-PCR", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 102}, {"term": "point-of-care test", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 124}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Safety and efficacy of inhaled nebulised interferon beta-1a ( SNG001 ) for treatment of SARS-CoV-2 infection : a randomised , double-blind , placebo-controlled, phase 2 trial .", "Evidence Elements": {"Participant": [{"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 108}], "Intervention": [{"term": "inhaled nebulised interferon beta-1a ( SNG001 )", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 70}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection carries a substantial risk of severe and prolonged illness ; treatment options are currently limited .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We assessed the efficacy and safety of inhaled nebulised interferon beta-1a ( SNG001 ) for the treatment of patients admitted to hospital with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 137}], "Intervention": [{"term": "inhaled nebulised interferon beta-1a ( SNG001 )", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 86}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 24}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 35}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We did a randomised , double-blind , placebo-controlled, phase 2 pilot trial at nine UK sites .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Adults aged 18 years or older and admitted to hospital with COVID-19 symptoms , with a positive RT-PCR or point-of-care test , or both , were randomly assigned ( 1:1 ) to receive SNG001 ( 6 MIU ) or placebo by inhalation via a mouthpiece daily for 14 days .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 54}, {"term": "COVID-19 symptoms", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 77}, {"term": "positive RT-PCR", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 102}, {"term": "point-of-care test", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 124}], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 179, "end": 185}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 206}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the change in clinical condition on the WHO Ordinal Scale for Clinical Improvement ( OSCI ) during the dosing period in the intention-to-treat population ( all randomised patients who received at least one dose of the study drug ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "change in clinical condition on the WHO Ordinal Scale for Clinical Improvement ( OSCI )", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 115}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The OSCI is a 9-point scale , where 0 corresponds to no infection and 8 corresponds to death .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "no infection", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 65}], "Outcome": [{"term": "OSCI", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 8}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Multiple analyses were done to identify the most suitable statistical method for future clinical trials .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was assessed by monitoring adverse events for 28 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "adverse events", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 48}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This trial is registered with Clinicaltrialsregister.eu ( 2020-001023-14 ) and ClinicalTrials.gov ( NCT04385095 ) ; the pilot trial of inpatients with COVID-19 is now completed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between March 30 and May 30, 2020, 101 patients were randomly assigned to SNG001 ( n = 50 ) or placebo ( n = 51 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 80}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "48 received SNG001 and 50 received placebo and were included in the intention-to-treat population .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 18}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 42}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "66 ( 67 % ) patients required oxygen supplementation at baseline : 29 in the placebo group and 37 in the SNG001 group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 84}], "Outcome": [{"term": "oxygen supplementation", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 52}], "Observation": [], "Count": [{"term": "66 ( 67 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 20}, {"term": "29", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 69}, {"term": "37", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 97}]}, "Evidence Propositions": [{"Intervention": "placebo", "Observation": "", "Count": "29", "Outcome": "oxygen supplementation"}]}, {"Section": "FINDINGS", "Text": "Patients receiving SNG001 had greater odds of improvement on the OSCI scale ( odds ratio 2\u00b732 [ 95 % CI 1\u00b707-5\u00b704 ] ; p=0\u00b7033 ) on day 15 or 16 and were more likely than those receiving placebo to recover to an OSCI score of 1 ( no limitation of activities ) during treatment ( hazard ratio 2\u00b719 [ 95 % CI 1\u00b703-4\u00b769 ] ; p=0\u00b7043 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 25}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 186, "end": 193}], "Outcome": [{"term": "odds of improvement on the OSCI scale", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 75}, {"term": "recover to an OSCI score of 1 ( no limitation of activities )", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 258}], "Observation": [{"term": "greater", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 37}, {"term": "more likely", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 164}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "greater", "Outcome": "", "Count": ""}, {"Intervention": ["SNG001", "placebo"], "Observation": "more likely", "Outcome": "recover to an OSCI score of 1 ( no limitation of activities )", "Count": ""}]}, {"Section": "FINDINGS", "Text": "SNG001 was well tolerated .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Outcome": [], "Observation": [{"term": "well tolerated", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 25}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The most frequently reported treatment-emergent adverse event was headache ( seven [ 15 % ] patients in the SNG001 group and five [ 10 % ] in the placebo group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 114}], "Outcome": [{"term": "headache", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 74}], "Observation": [{"term": "most frequently", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 19}], "Count": [{"term": "seven [ 15 % ] patients", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 100}, {"term": "five [", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 131}]}, "Evidence Propositions": [{"Intervention": [], "Observation": "most frequently", "Outcome": "headache", "Count": ""}]}, {"Section": "FINDINGS", "Text": "There were three deaths in the placebo group and none in the SNG001 group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 38}, {"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 67}], "Outcome": [{"term": "deaths", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 23}], "Observation": [], "Count": [{"term": "three", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 16}, {"term": "none", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 53}]}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo , providing a strong rationale for further trials .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SNG001", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 28}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 148}], "Outcome": [{"term": "odds of improvement", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 60}, {"term": "recovered", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 74}], "Observation": [{"term": "greater", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 40}, {"term": "more rapidly from SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 113}, {"term": "strong", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 169}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "greater", "Outcome": "", "Count": ""}, {"Intervention": [], "Observation": "more rapidly from SARS-CoV-2 infection", "Outcome": "", "Count": ""}]}, {"Section": "FUNDING", "Text": "Synairgen Research .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}